Data investigation
The Head-to-Head, and What It Settles
751 adults randomized to tirzepatide or semaglutide, each at maximum tolerated dose, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%, and on several other endpoints the answer runs the other way.
This is the trial everyone wanted. Seven hundred and fifty-one adults with obesity and without diabetes, randomized to tirzepatide or semaglutide, each at the highest dose they could tolerate, for 72 weeks. Tirzepatide produced 20.2% weight loss against 13.7%.[1] On weight, the question is settled. On several other questions this register has covered, the answer runs the other way.
Why this comparison is fair
Most claimed comparisons between these two drugs are not comparisons at all. They set one trial’s headline beside another’s, which measures the trials as much as the drugs. This trial is different: it randomized one group of participants to the two drugs, over the same period, under the same protocol.
It also avoids the criticism that sank an earlier comparison. Both arms ran to their own maximum tolerated dose: tirzepatide at 10 or 15 mg, semaglutide at 1.7 or 2.4 mg. Semaglutide 2.4 mg is its full weight-management dose, so nobody was held back. That answers the objection we raised about a different analysis, which set tirzepatide’s full range against semaglutide at the 1 mg diabetes dose (see a composite is only its components). Because Mounjaro is the same tirzepatide under a diabetes label, this is also the trial behind most Wegovy and Mounjaro comparisons.
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Weight change | −20.2% (95% CI −21.4 to −19.1) | −13.7% (−14.9 to −12.6) |
| Waist circumference | −18.4 cm | −13.0 cm |
| Reaching 10%, 15%, 20% and 25% loss | More likely at every threshold | — |
Both differences reached P<0.001. Gastrointestinal effects dominated in both arms, mostly mild to moderate, mostly during dose escalation.
The design flaw that is worth naming
This is unavoidable to a degree, since the two drugs titrate differently and blinding would require elaborate dummy injections. It is still the reason a 6.5 percentage point gap should be read as approximately right rather than precisely measured.
The trial was funded by Eli Lilly, which makes tirzepatide. That is normal for a phase 3b head-to-head, and it still belongs on the page when the sponsor’s drug won.
What 'better' does not follow from
Tirzepatide removes more weight. Whether it is the better drug depends on which outcome you are buying, and on several of them our other articles have found a different answer, including one from this same trial.
| Question | What the evidence says |
|---|---|
| Quality of life, in this trial | Mental component improved in neither arm over 72 weeks — details |
| Preventing death | Subcutaneous semaglutide is the only drug with a mortality signal across 262 trials — details |
| Heart failure outcomes | No meaningful difference between them (HR 0.86, 0.70–1.06) — details |
| Lean mass | Tirzepatide loses the most fat (25.7%) and the most lean mass (8.3%) — details |
| Does the benefit track the weight? | In SELECT, cardiovascular protection was largely independent of weight lost — details |
| Value for money | A lifetime cost model built on this trial projects tirzepatide saving $41,688 per patient; it was computed, not measured |
The drug that removes more weight is not the drug with the outcome evidence.
That is not a reason to prefer semaglutide either. It means “which is better” hides a second question, better at what, and the answer changes depending on how you fill it in.
How to actually use this
- If the goal is the largest weight reduction, this trial answers it directly and in tirzepatide’s favor.
- If the goal is cardiovascular risk with established disease, the evidence depends on who you are. Semaglutide has placebo-controlled outcome trials, including SELECT in people with overweight or obesity and no diabetes. In type 2 diabetes with heart disease, tirzepatide now has SURPASS-CVOT, where it was noninferior to dulaglutide but did not reach superiority (hazard ratio 0.92; 95.3% CI, 0.83 to 1.01).[2] In obesity without diabetes, tirzepatide has no outcomes result yet; SURMOUNT-MMO is still running.[3]
- Tolerability is individual and not settled by a group mean. The drug you can stay on beats the drug you stop, and slower titration has randomized evidence behind it (see five clicks).
- Cost, coverage and supply decide this for most people more often than either trial does.
For each drug’s own record on its own terms, see the tirzepatide timeline and the semaglutide timeline.
Frequently Asked Questions
References
- 1.Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine. 2025. PMID: 40353578.
- 2.Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England Journal of Medicine. 2025. PMID: 41406444.
- 3.Eli Lilly and Company A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO), NCT05556512 ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT05556512
Compare the sellers
Related research
What 262 Trials Say Together
262 trials, 99,791 people, 19 drugs, every result graded. Three of its findings cut against how this field is described, starting with the fact that the drug with the mortality evidence is not the one that takes off the most weight.
9 min read
Where the Evidence Is Strongest
Most of what this register examines has something wrong with it. This does not: a synthesis of 13 trials rates the cardiovascular and kidney benefits in chronic kidney disease at high certainty.
7 min read
Losing Weight Predicted More Heart Attacks
A prespecified analysis of 17,604 people found semaglutide's cardiovascular protection largely independent of weight lost. In the placebo arm, losing weight predicted more cardiac events.
7 min read
The One Place People Felt Better
No obesity drug improved general quality of life across 43 trials. Both heart failure trials produced large symptom improvements. Those findings are not in conflict, because the heart failure trials used a disease-specific symptom measure.
8 min read
How Far You Can Walk
Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.
6 min read
When Pooling Studies Hides the Answer
A meta-analysis of 323,439 patients found no significant cardiovascular advantage for tirzepatide. The more important number sits beside it: the studies being pooled disagree with each other almost completely.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
MyDrHank
An oral route if you will not self-inject
From $171/mo, prepaid
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →